DNA vaccination against membrane-bound Kit ligand: a new approach to inhibiting tumour growth and angiogenesis.

[1]  Paula T Hammond,et al.  Polymer multilayer tattooing for enhanced DNA vaccination. , 2013, Nature materials.

[2]  Jonathan B. Mitchem,et al.  Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. , 2013, Cancer research.

[3]  A. Rathinavelu,et al.  A novel regulation of VEGF expression by HIF-1α and STAT3 in HDM2 transfected prostate cancer cells , 2012, Journal of cellular and molecular medicine.

[4]  B. Groner,et al.  c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer , 2012, Oncogene.

[5]  P. Dentelli,et al.  IL-3 is a novel target to interfere with tumor vasculature , 2011, Oncogene.

[6]  D. Hanahan,et al.  Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. , 2011, Blood.

[7]  Lei Xu,et al.  Normalization of the vasculature for treatment of cancer and other diseases. , 2011, Physiological reviews.

[8]  P. Dentelli,et al.  RETRACTED ARTICLE: MIR221/MIR222-driven post-transcriptional regulation of P27KIP1 and P57KIP2 is crucial for high-glucose- and AGE-mediated vascular cell damage , 2011, Diabetologia.

[9]  R. Herbst,et al.  Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. , 2011, The Journal of clinical investigation.

[10]  E. Giovannetti,et al.  Tyrosine kinase inhibitors: Multi-targeted or single-targeted? , 2011, World journal of clinical oncology.

[11]  P. Carmeliet,et al.  Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. , 2011, Current opinion in genetics & development.

[12]  Federica Cavallo,et al.  2011: the immune hallmarks of cancer , 2011, Cancer Immunology, Immunotherapy.

[13]  P. Dentelli,et al.  Inhibition of β1 integrin and IL-3Rβ common subunit interaction hinders tumour angiogenesis , 2010, Oncogene.

[14]  X. Paoletti,et al.  Development of anti-cancer drugs. , 2010, Discovery medicine.

[15]  Francesca Orso,et al.  microRNA-222 Controls Neovascularization by Regulating Signal Transducer and Activator of Transcription 5A Expression , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[16]  K. Pietras,et al.  Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma , 2010, Oncogene.

[17]  R. Bicknell,et al.  Anticancer strategies involving the vasculature , 2009, Nature Reviews Clinical Oncology.

[18]  Y. Yonemitsu,et al.  III. Angiogenesis: complexity of tumor vasculature and microenvironment. , 2009, Current pharmaceutical design.

[19]  A. Gown,et al.  A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338. , 2008, Clinical breast cancer.

[20]  H. Xiong,et al.  SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. , 2008, Blood.

[21]  C. Divino,et al.  Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. , 2008, Blood.

[22]  M. Colombo,et al.  Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy , 2007, Nature Reviews Cancer.

[23]  Federica Cavallo,et al.  Are oncoantigens suitable targets for anti-tumour therapy? , 2007, Nature Reviews Cancer.

[24]  Susan M. Schlenner,et al.  Kit is essential for PMA-inflammation-induced mast-cell accumulation in the skin. , 2007, Blood.

[25]  Giovanni Camussi,et al.  C-KIT, by interacting with the membrane-bound ligand, recruits endothelial progenitor cells to inflamed endothelium. , 2007, Blood.

[26]  S. Verma,et al.  Stem Cell Factor Attenuates Vascular Smooth Muscle Apoptosis and Increases Intimal Hyperplasia After Vascular Injury , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[27]  P. Musiani,et al.  A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Federica Cavallo,et al.  Vaccines for tumour prevention , 2006, Nature Reviews Cancer.

[29]  Jung Weon Lee,et al.  The FASEB Journal express article 10.1096/fj.04-3099fje. Published online May 26, 2005. ©2005 FASEB , 2022 .

[30]  A. Mantovani,et al.  Smoldering and polarized inflammation in the initiation and promotion of malignant disease. , 2005, Cancer cell.

[31]  G. Camussi,et al.  Altered angiogenesis and survival in human tumor‐derived endothelial cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  Y. Kitamura,et al.  Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation. , 2003, Blood.

[33]  J. Becker,et al.  A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth , 2002, Nature Medicine.

[34]  P. Musiani,et al.  Tumor Rejection and Immune Memory Elicited by Locally Released LEC Chemokine Are Associated with an Impressive Recruitment of APCs, Lymphocytes, and Granulocytes1 , 2000, The Journal of Immunology.

[35]  D. Toksoz,et al.  The membrane-bound isoform of stem cell factor synergizes with soluble flt3 ligand in supporting early hematopoietic cells in long-term cultures of normal and aplastic anemia bone marrow. , 1998, Experimental hematology.

[36]  P. Musiani,et al.  Cytokines, tumour-cell death and immunogenicity: a question of choice. , 1997, Immunology today.

[37]  A. Hakura,et al.  Abrogation of c-kit/Steel factor-dependent tumorigenesis by kinase defective mutants of the c-kit receptor: c-kit kinase defective mutants as candidate tools for cancer gene therapy. , 1996, Cancer research.

[38]  D. Williams,et al.  Membrane-bound Steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form. , 1995, Blood.

[39]  E. Huang,et al.  Differential expression and processing of two cell associated forms of the kit-ligand: KL-1 and KL-2. , 1992, Molecular biology of the cell.

[40]  B. Leclair,et al.  Expression of stem cell factor and c-kit mRNA in cultured endothelial cells, monocytes and cloned human bone marrow stromal cells (CFU-RF). , 1992, Experimental hematology.

[41]  B. Clarkson.  Retinoic acid in acute promyelocytic leukemia: the promise and the paradox. , 1991, Cancer cells.